Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8116 to 8130 of 8216 results

  1. Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]

    In development [GID-TA11132] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  2. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development [GID-TA11443] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]

    In development [GID-TA11418] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  4. Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]

    In development [GID-TA11131] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Acute kidney injury: prevention, detection and management - Assessing risk factors for acute kidney injury in adults having iodine-based contrast media

    In development [GID-NG10410] Expected publication date: 16 October 2024

    NICE guideline
    In development

  6. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    Awaiting development [GID-TA11025] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development [GID-TA10971] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Tirzepatide for managing overweight and obesity [ID6179]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 25 June 2024.

    Technology appraisal guidance
    In consultation

  9. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    Awaiting development [GID-TA11092] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

    Awaiting development [GID-TA11094] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]

    Awaiting development [GID-TA11099] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]

    Awaiting development [GID-TA11101] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic device

    In development [GID-DG10080] Expected publication date: 22 August 2024

    Diagnostics guidance
    In development

  14. Insulin icodec for treating type 1 and type 2 diabetes ID6175

    In development [GID-TA11104] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Adrenal insufficiency: identification and management

    In development [GID-NG10237] Expected publication date: 28 August 2024

    NICE guideline
    In development